Are there any upcoming catalysts (e.g., data readouts, regulatory submissions, or partnership announcements) that could move the stock in the short term?

Short‑term catalyst outlook

The Q2‑2025 earnings release is the first public update from SCYNEXIS in more than a year, and the filing itself does not disclose any new data milestones. However, the “corporate update” portion of the release typically flags the next set of value‑driving events that the market will price in. In SCYNEXIS’ case the most likely near‑term catalysts are:

Trading implications

• Technical view: SCYX has been trading in a tight range around the $2.00‑$2.30 band since the Q2 release, with the 20‑day SMA hovering near $2.15 and the RSI stuck in the 45‑55 zone – a classic “waiting for a catalyst” setup. A breakout above $2.30 with volume would likely be the first price reaction to any of the above events, while a breach below $2.00 could trigger a short‑cover rally if data disappoint.
  
• Actionable stance: Keep a long‑biased, catalyst‑play position with a tight stop just below the recent low (~$1.95). If a Phase 2/3 readout or FDA meeting is confirmed (e.g., via a 8‑K filing or conference call agenda), consider scaling in on a breakout. Conversely, if the company signals a delay or a negative data trend, be ready to unwind quickly, as the short‑term upside is limited without a clear value‑adding event.
  

In short, the primary short‑term drivers for SCYNEXIS will be the upcoming clinical data readout and the expected FDA interaction in Q3‑Q4 2025. Those dates are the key windows where the stock can experience meaningful volatility and present trading opportunities.